Company: SXTPW
Filing Date: 2025-07-07
Form Type: S-1
Source: 0001213900-25-061842
Chunk: 2

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-07
Form: S-1
Chunk 2
---
 of Common Stock

or

Pre-Funded Warrants to Purchase up to 2,036,659 Shares of Common Stock
Series A-1 Warrants to Purchase up to 2,036,659 Shares of Common Stock

Series A-2 Warrants to Purchase up to 2,036,659 Shares of Common Stock

Up to 6,109,977 Shares of Common Stock Issuable Upon Exercise of the Series A-1 Warrants, Series A-2 Warrants and Pre-Funded Warrants

60 Degrees Pharmaceuticals, Inc.</div>

We are offering up to 2,036,659 shares of
common stock, par value $0.0001 per share, together with accompanying Series A-1 warrants (the “Series A-1 Warrants”) to purchase
up to 2,036,659 shares of common stock, and Series A-2 Warrants (the “Series A-2 Warrants” and, together with the Series A-1
Warrants, the “Warrants”) to purchase up to 2,036,659 shares of common stock, pursuant to this prospectus. The combined
assumed public offering price for each share of common stock and accompanying Series A-1 Warrant and Series A-2 Warrant is $2.455, the
last reported sale price of our common stock on The Nasdaq Capital Market on July 2, 2025. Each Warrant will have an assumed exercise
price of $2.455 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon
exercise of the Warrants (“Warrant Stockholder Approval”), provided, however, if the Pricing Conditions (as defined below)
are met, the Warrants will be exercisable upon issuance (the “Initial Exercise Date”). The Series A-1 Warrant will expire
on the fifth anniversary of the Initial Exercise Date. The Series A-2 Warrant will expire on the eighteen (18) month anniversary of the
Initial Exercise Date. The shares of common stock and any pre-funded warrants in lieu thereof and accompanying Warrants are immediately
separable and will be issued separately in this offering. As used herein “Pricing Conditions” mean that the combined offering
price per share and accompanying Warrants is such that the Warrant Stockholder Approval is not required under the rules of The Nasdaq
Stock Market LLC (“Nasdaq”) because either (i) the offering is an at-the-market offering under